Fresenius Medical Care AG/€FME
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Fresenius Medical Care AG
Fresenius Medical Care, listed under the ticker FME, is a global provider of dialysis services and products for individuals diagnosed with chronic kidney failure. Founded in 1996 and headquartered in Bad Homburg, Germany, the company operates in the healthcare sector. Beyond dialysis, Fresenius Medical Care offers a range of other services, including hospital management and related healthcare services, advancing its position as a comprehensive healthcare provider internationally.
Ticker
€FME
Sector
Primary listing
XETRA
Employees
112,445
Headquarters
Website
FME Metrics
BasicAdvanced
€14B
21.09
€2.23
0.88
€1.44
3.06%
Price and volume
Market cap
€14B
Beta
0.88
52-week high
€54.02
52-week low
€35.00
Average daily volume
9K
Dividend rate
€1.44
Financial strength
Current ratio
1.437
Quick ratio
0.874
Long term debt to equity
65.759
Total debt to equity
76.953
Dividend payout ratio (TTM)
64.37%
Interest coverage (TTM)
4.03%
Profitability
EBITDA (TTM)
2,485.701
Gross margin (TTM)
24.67%
Net profit margin (TTM)
3.36%
Operating margin (TTM)
8.10%
Effective tax rate (TTM)
27.29%
Revenue per employee (TTM)
€170,000
Management effectiveness
Return on assets (TTM)
3.03%
Return on equity (TTM)
5.72%
Valuation
Price to earnings (TTM)
21.094
Price to revenue (TTM)
0.707
Price to book
0.96
Price to tangible book (TTM)
-8.62
Price to free cash flow (TTM)
6.768
Free cash flow yield (TTM)
14.78%
Free cash flow per share (TTM)
6.951
Dividend yield (TTM)
3.06%
Forward dividend yield
3.06%
Growth
Revenue change (TTM)
0.53%
Earnings per share change (TTM)
23.43%
3-year revenue growth (CAGR)
2.00%
10-year revenue growth (CAGR)
3.04%
3-year earnings per share growth (CAGR)
-6.74%
10-year earnings per share growth (CAGR)
-2.80%
3-year dividend per share growth (CAGR)
2.17%
10-year dividend per share growth (CAGR)
6.00%
What the Analysts think about FME
Analyst ratings (Buy, Hold, Sell) for Fresenius Medical Care AG stock.
Bulls say / Bears say
Fresenius Medical Care beat Q1 2025 estimates with revenues of €4.88 billion and adjusted operating income of €457 million, driving a 2.7% share price increase and confirming its full-year outlook (Reuters).
The company unveiled a €1 billion share buyback programme, signaling confidence in its cash-flow generation and a commitment to enhanced shareholder returns (Reuters).
Management reaffirmed strong profitability targets, projecting high-teens to high-twenties percent operating income growth for 2025 with an 11–12% margin and a mid-teens operating margin by 2030, supported by €300 million in cost savings initiatives (Reuters).
A proposed class action lawsuit filed in Colorado alleges Fresenius Medical Care conspired with DaVita to inflate dialysis treatment costs through anti-competitive practices, exposing the company to significant legal liabilities and reputational damage (Reuters).
The €1 billion share buyback announced in June, combined with planned annual capital expenditures of up to €1 billion, may strain free cash flow and limit Fresenius Medical Care’s flexibility for strategic investments or R&D (Reuters).
High flu and cold cases in February led to missed dialysis treatments in the U.S. during Q1, underscoring Fresenius Medical Care’s operational vulnerability to external health-related disruptions and volume volatility (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 29 Sept 2025.
FME Financial Performance
Revenues and expenses
FME Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Fresenius Medical Care AG stock?
Fresenius Medical Care AG (FME) has a market cap of €14B as of October 26, 2025.
What is the P/E ratio for Fresenius Medical Care AG stock?
The price to earnings (P/E) ratio for Fresenius Medical Care AG (FME) stock is 21.09 as of October 26, 2025.
Does Fresenius Medical Care AG stock pay dividends?
Yes, the Fresenius Medical Care AG (FME) stock pays dividends to shareholders. As of October 26, 2025, the dividend rate is €1.44 and the yield is 3.06%. Fresenius Medical Care AG has a payout ratio of 64.37% on a trailing twelve-month basis.
When is the next Fresenius Medical Care AG dividend payment date?
The next Fresenius Medical Care AG (FME) dividend payment date is unconfirmed.
What is the beta indicator for Fresenius Medical Care AG?
Fresenius Medical Care AG (FME) has a beta rating of 0.88. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.